# HAEMONETICS CORP (HAE) Informational only - not investment advice. CIK: 0000313143 SIC: 3841 Surgical & Medical Instruments & Apparatus SIC breadcrumb: [Manufacturing](/division/D/) > [SIC Major Group 38](/major-group/38/) > [SIC 3841 Surgical & Medical Instruments & Apparatus](/industry/3841/) Latest 10-K filed: 2026-05-20 SEC page: https://www.sec.gov/edgar/browse/?CIK=313143 Filing source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/hae-20260328.htm ## At a glance FY2026 · period end 2026-03-28 · filed 2026-05-20 · accession 0000313143-26-000050 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000313143.json | Metric | Value | FY | Provenance | | --- | ---: | ---: | --- | | Revenue | 1,334,027,000 USD | 2026 | verified | | Net income | 97,308,000 USD | 2026 | verified | | Assets | 2,395,925,000 USD | 2026 | verified | | Free cash flow | 260,441,000 USD | 2026 | computed | | Net margin | 7.29% | 2026 | computed | | Operating margin | 11.75% | 2026 | computed | | Revenue YoY | -1.97% | 2026 | computed | | ROE | 12.22% | 2026 | computed | Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2026 revenue ÷ FY2025 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity. No market price, no rating, no forecast on this site. Not investment advice. ### Peer percentile fingerprint | Ratio | HAE | Peer median | Percentile | N | | --- | ---: | ---: | ---: | ---: | | Net margin | 7.3% | -6.0% | 66 | 63 | | Operating margin | 11.7% | -2.7% | 69 | 63 | | Revenue growth | -2.0% | 13.6% | 11 | 64 | | FCF margin | 19.5% | 0.2% | 89 | 63 | | ROE | 12.2% | -9.1% | 74 | 58 | | ROA | 4.1% | -4.8% | 67 | 65 | | Liabilities / equity | 2.01 | 0.89 | 73 | 63 | | Current ratio | 2.95 | 3.23 | 45 | 65 | Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 3841 Surgical & Medical Instruments & Apparatus, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking. ## Selected Fundamentals | Metric | Value | Unit | FY | Filed | | --- | ---: | --- | ---: | --- | | Revenue | 1334027000 | USD | 2026 | 2026-05-20 | | Net income | 97308000 | USD | 2026 | 2026-05-20 | | Assets | 2395925000 | USD | 2026 | 2026-05-20 | ## Financials Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-05-20. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000313143.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts. | Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | | | | | | 993,196,000 | 1,168,660,000 | 1,309,055,000 | 1,360,824,000 | 1,334,027,000 | | Net income | -26,268,000 | 45,572,000 | 55,019,000 | 76,526,000 | 79,469,000 | 43,375,000 | 115,401,000 | 117,558,000 | 167,679,000 | 97,308,000 | | Operating income | -19,381,000 | 56,157,000 | 83,545,000 | 103,351,000 | 89,747,000 | 80,750,000 | 156,033,000 | 164,883,000 | 221,817,000 | 156,734,000 | | Gross profit | 378,494,000 | 411,908,000 | 417,536,000 | 484,513,000 | 397,838,000 | 505,502,000 | 615,097,000 | 691,548,000 | 748,958,000 | 787,586,000 | | Diluted EPS | -0.51 | 0.85 | 1.04 | 1.48 | 1.55 | 0.84 | 2.24 | 2.29 | 3.31 | 2.05 | | Operating cash flow | 159,738,000 | 220,350,000 | 159,281,000 | 158,217,000 | 108,805,000 | 172,263,000 | 273,058,000 | 181,751,000 | 181,725,000 | 293,221,000 | | Capital expenditures | 76,135,000 | 74,799,000 | 118,961,000 | 48,758,000 | 37,040,000 | 96,509,000 | 191,327,000 | 38,125,000 | 39,278,000 | 32,780,000 | | Share buybacks | 0.00 | 100,000,000 | 160,000,000 | 175,000,000 | 0.00 | 0.00 | 75,000,000 | 0.00 | 225,000,000 | 175,000,000 | | Assets | 1,238,709,000 | 1,237,339,000 | 1,274,767,000 | 1,267,110,000 | 1,819,923,000 | 1,859,734,000 | 1,934,825,000 | 2,195,591,000 | 2,450,948,000 | 2,395,925,000 | | Stockholders' equity | 739,610,000 | 752,429,000 | 667,868,000 | 587,109,000 | 731,670,000 | 749,424,000 | 817,997,000 | 959,959,000 | 820,836,000 | 796,320,000 | | Cash and cash equivalents | 139,564,000 | 180,169,000 | 169,351,000 | 137,311,000 | 192,305,000 | 259,496,000 | 284,466,000 | 178,800,000 | 306,763,000 | 245,440,000 | | Free cash flow | 83,603,000 | 145,551,000 | 40,320,000 | 109,459,000 | 71,765,000 | 75,754,000 | 81,731,000 | 143,626,000 | 142,447,000 | 260,441,000 | ### Ratios ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported. | Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Net margin | | | | | | 4.37% | 9.87% | 8.98% | 12.32% | 7.29% | | Operating margin | | | | | | 8.13% | 13.35% | 12.60% | 16.30% | 11.75% | | Return on equity | -3.55% | 6.06% | 8.24% | 13.03% | 10.86% | 5.79% | 14.11% | 12.25% | 20.43% | 12.22% | | Return on assets | -2.12% | 3.68% | 4.32% | 6.04% | 4.37% | 2.33% | 5.96% | 5.35% | 6.84% | 4.06% | | Liabilities / equity | 0.67 | 0.64 | 0.91 | 1.16 | 1.49 | 1.48 | 1.37 | 1.29 | 1.99 | 2.01 | | Current ratio | 2.42 | 1.35 | 2.44 | 2.20 | 2.74 | 1.71 | 3.06 | 2.56 | 1.62 | 2.95 | ## As-reported value updates 2 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period. Ledger: /company/HAE/revisions/ ## Quarterly Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-06. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000313143.json. Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived. | Quarter | End date | Revenue | Net income | Diluted EPS | Method | | --- | --- | ---: | ---: | ---: | --- | | 2023-Q2 | 2022-10-01 | | | 0.64 | reported discrete quarter | | 2023-Q3 | 2022-12-31 | | | 0.64 | reported discrete quarter | | 2024-Q1 | 2023-07-01 | | | 0.80 | reported discrete quarter | | 2024-Q2 | 2023-07-01 | | 41,042,000 | | reported discrete quarter | | 2024-Q2 | 2023-09-30 | 318,183,000 | | 0.48 | reported discrete quarter | | 2024-Q3 | 2023-09-30 | | 24,908,000 | | reported discrete quarter | | 2024-Q3 | 2023-12-30 | 336,250,000 | | 0.61 | reported discrete quarter | | 2024-Q4 | 2024-03-30 | 343,290,000 | 20,367,000 | | derived Q4 = FY annual - nine-month YTD | | 2025-Q1 | 2024-06-29 | 336,172,000 | 38,373,000 | 0.74 | reported discrete quarter | | 2025-Q2 | 2024-06-29 | | 38,373,000 | | reported discrete quarter | | 2025-Q2 | 2024-09-28 | 345,511,000 | | 0.66 | reported discrete quarter | | 2025-Q3 | 2024-09-28 | | 33,831,000 | | reported discrete quarter | | 2025-Q3 | 2024-12-28 | 348,542,000 | | 0.74 | reported discrete quarter | | 2025-Q4 | 2025-03-29 | 330,599,000 | 57,981,000 | | derived Q4 = FY annual - nine-month YTD | | 2026-Q1 | 2025-06-28 | 321,394,000 | 34,031,000 | 0.70 | reported discrete quarter | | 2026-Q2 | 2025-06-28 | | 34,031,000 | | reported discrete quarter | | 2026-Q2 | 2025-09-27 | 327,315,000 | | 0.81 | reported discrete quarter | | 2026-Q3 | 2025-09-27 | | 38,684,000 | | reported discrete quarter | | 2026-Q3 | 2025-12-27 | 338,967,000 | | 0.95 | reported discrete quarter | | 2026-Q4 | 2026-03-28 | 346,351,000 | -20,147,000 | | derived Q4 = FY annual - nine-month YTD | | 2027-Q1 | 2026-06-27 | 339,380,000 | 33,010,000 | 0.72 | reported discrete quarter | ## Filed narrative (10-K & 10-Q) ## Business Verbatim Item 1 Business section from HAE's latest 10-K: [/company/HAE/business/](/company/HAE/business/). ## Risk Factors Verbatim Item 1A Risk Factors from HAE's latest 10-K: [/company/HAE/risk-factors/](/company/HAE/risk-factors/). ## Latest quarter (10-Q) Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000120/hae-20260627.htm Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Confidence: high Filing date: 2026-08-06 Report date: 2026-06-27 ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with both our interim condensed consolidated financial statements and notes thereto which appear elsewhere in this Quarterly Report on Form 10-Q and our annual consolidated financial statements, notes thereto and the MD&A contained in our Annual Report on Form 10-K for the fiscal year ended March 28, 2026. The following discussion may contain forward-looking statements and should be read in conjunction with the “Cautionary Statement Regarding Forward-Looking Information” in this discussion. When used in this report, the terms “we,” “us,” “our,” “Haemonetics” and the “Company” mean Haemonetics Corporation. Introduction Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. We view our operations and manage our business in two reporting segments: Apheresis and MedSurg. For that purpose, “Apheresis” includes plasma collection devices and disposables for plasma, red cells and platelets, donor management software and supporting software solutions sold to plasma customers, blood collection and processing devices. “MedSurg” is comprised of Interventional Technologies, which includes Vascular Closure, Sensor-Guided Technologies and Esophageal Protection product lines, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. Recent Developments Segment Organization Realignment On June 5, 2026, we implemented an organizational realignment designed to align our commercial operations into two global reportable segments by combining the previously reported Plasma and Blood Center reportable segments into Apheresis and renaming the Hospital reportable segment to MedSurg. This organizational structure reflects how the Company is organized to manage operations, allocate resources and evaluate performance. Revolving Credit Facility Repayment In connection with the settlement of the convertible senior notes due in 2026, we borrowed $300.0 million under our revolving credit facility pursuant to our second amended and restated credit agreement. During the first quarter of fiscal 2027, we repaid $50.0 million of the outstanding amount under the revolving credit facility. As of June 27, 2026, $250.0 million remained outstanding under the revolving credit facility. During the second quarter of fiscal 2027, we repaid an additional $50.0 million on the revolving credit facility. 28 Table of Contents Financial Summary [[GREPCENT_TABLE]] [["","","","Three Months Ended"],["","","","","","","","June 27, 2026","","June 28, 2025","","Reported change"],["","","","","","","","(Dollars in Thousands, Except Per Share Data)"],["Net revenues","","","","","","","$","339,380","","","$","321,394","","","5.6","%"],["Gross profit","","","","","","","$","202,803","","","$","192,244","","","5.5","%"],["% of net revenues","","","","","","","59.8","%","","59.8","%"],["Operating expenses","","","","","","","$","145,345","","","$","138,372","","","5.0","%"],["Operating income","","","","","","","$","57,458","","","$","53,872","","","6.7","%"],["% of net revenues","","","","","","","16.9","%","","16.8","%"],["Interest and other expense, net","","","","","","","$","(9,884)","","","$","(8,703)","","","13.6","%"],["Income before provision for income taxes","","","","","","","$","47,574","","","$","45,169","","","5.3","%"],["Provision for income taxes","","","","","","","$","14,564","","","$","11,138","","","30.8","%"],["% of pre-tax income","","","","","","","30.6","%","","24.7","%"],["Net income","","","","","","","$","33,010","","","$","34,031","","","(3.0)","%"],["% of net revenues","","","","","","","9.7","%","","10.6","%"],["Net income per share \u2013 basic","","","","","","","$","0.73","","","$","0.71","","","2.8","%"],["Net income per share \u2013 diluted","","","","","","","$","0.72","","","$","0.70","","","2.9","%"]] [[/GREPCENT_TABLE]] Net revenues increased 5.6% during the three months ended June 27, 2026 as compared with the same period of fiscal 2026. This was primarily attributable to revenue increases in Apheresis, driven by volume growth and share gains within the Plasma franchise, and revenue increases in MedSurg, driven by share gains in the Hemostasis Management and Transfusion Management product lines within the Blood Management Technologies franchise. Operating income increased 6.7% during the three months ended June 27, 2026 as compared with the same period of fiscal 2026. The increase during the three months ended June 27, 2026 was primarily due to favorable product mix across all business units, as well as decreased amortization of fair value inventory step-up related to the acquisition of Advanced Cooling Therapy, Inc., d/b/a Attune Medical (“Attune Medical”). Management’s Use of Non-GAAP Measures Management uses non-GAAP financial measures, in addition to financial measures in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with U.S. GAAP. Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency conversion rate. We have provided this non-GAAP financial measure because we believe it provides meaningful information regarding our results on a consistent and comparable basis for the periods presented. 29 Table of Contents Results of Operations Net Revenues by Geography [[GREPCENT_TABLE]] [["","Three Months Ended"],["","June 27, 2026","","June 28, 2025","","Reported change","","Currency impact","","Constant currency change (1)"],["","(Dollars in Thousands)"],["United States","$","257,844","","","$","242,404","","","6.4","%","","\u2014","%","","6.4","%"],["International","81,536","","","78,990","","","3.2","%","","0.7","%","","2.5","%"],["Net revenues","$","339,380","","","$","321,394","","","5.6","%","","0.2","%","","5.4","%"]] [[/GREPCENT_TABLE]] __________ (1)    Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency. See “Management’s Use of Non-GAAP Measures.” Our principal operations are in the United States, Europe, Japan and other parts of Asia. We market and sell our products in approximately 90 countries through a combination of our direct sales force and independent distributors. During the three months ended June 27, 2026, our revenue generated outside the U.S. was 24.0% of total net revenues, as compared with 24.6% during the three months ended June 28, 2025. International sales are generally conducted in local currencies, primarily Japanese Yen, Euro and Chinese Yuan. Our results of operations are impacted by changes in foreign exchange rates, particularly in the value of the Yen, Euro and Yuan, relative to the U.S. Dollar. We have placed foreign currency hedges on certain foreign currencies to mitigate our exposure to foreign currency fluctuations. Please see the section entitled “Foreign Exchange” in this discussion for a more complete explanation of how foreign currency affects our business and our strategy for managing this exposure. Net Revenues by Business Unit [[GREPCENT_TABLE]] [["","Three Months Ended"],["","June 27, 2026","","June 28, 2025","","Reported change","","Currency impact","","Constant currency change(1)"],["","(Dollars in Thousands)"],["Apheresis"],["Plasma","$","155,524","","","$","145,074","","","7.2","%","","0.1","%","","7.1","%"],["Other(2)","35,794","","","36,662","","","(2.4)","%","","0.4","%","","(2.8)","%"],["Apheresis net revenues","$","191,318","","","$","181,736","","","5.3","%","","0.2","%","","5.1","%"],["MedSurg"],["Interventional Technologies(3)","$","59,942","","","$","58,483","","","2.5","%","","(0.3)","%","","2.8","%"],["Blood Management Technologies(4)","88,120","","","81,175","","","8.6","%","","0.5","%","","8.1","%"],["MedSurg net revenues","$","148,062","","","$","139,658","","","6.0","%","","0.1","%","","5.9","%"],["Total net revenues","$","339,380","","","$","321,394","","","5.6","%","","0.2","%","","5.4","%"]] [[/GREPCENT_TABLE]] __________ (1)    Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency. See “Management’s Use of Non-GAAP Measures.” (2)    Other includes blood collection and processing devices and disposables. (3)    Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the MedSurg business unit. (4)    Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the MedSurg business unit. Apheresis Apheresis revenue increased by 5.3% on an as reported basis and by 5.1% without the effect of foreign exchange during the three months ended June 27, 2026, as compared with the same period of fiscal 2026. The increase was primarily driven by volume growth and share gains within the Plasma franchise. 30 Table of Contents MedSurg MedSurg revenue increased by 6.0% on an as reported basis and by 5.9% without the effect of foreign exchange during the three months ended June 27, 2026, as compared with the same period of fiscal 2026. The increase was driven by higher market expansion in the Vascular Closure product line within the Interventional Technologies franchise, and by increased volume and share gains in the Hemostasis Management product line within the Blood Management Technologies franchise. Gross Profit [[GREPCENT_TABLE]] [["","Three Months Ended"],["","June 27, 2026","","June 28, 2025","","Reported change","","Currency impact","","Constant currency change(1)"],["","(Dollars in Thousands)"],["Gross profit","$","202,803","","","$","192,244","","","5.5","%","","\u2014","%","","5.5","%"],["% of net revenues","59.8","%","","59.8","%"]] [[/GREPCENT_TABLE]] __________ (1)    Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency. See “Management’s Use of Non-GAAP Measures.” Gross profit increased by 5.5% on an as reported basis and by 5.5% without the effect of foreign exchange during the three months ended June 27, 2026, as compared with the same period of fiscal 2026. The increase was driven primarily by the continued transformation of the product portfolio to higher margin offerings, benefits from product innovation, and the absence of amortization of fair value inventory step-up related to the Attune Medical acquisition. Operating Expenses [Excerpt truncated for page length; source filing is linked above.] ## Latest 10-K MD&A (excerpt) Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/hae-20260328.htm Complete FY 2026 MD&A: /company/HAE/mda/fy2026/ Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Confidence: high Filing date: 2026-05-20 Report date: 2026-03-28 ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Our Business Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. We view our operations and manage our business in three principal reporting segments: Plasma, Blood Center and Hospital. For that purpose, “Plasma” includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. “Blood Center” includes blood collection and processing devices and disposables for plasma, red cells and platelets. “Hospital” is comprised of Interventional Technologies, which includes Vascular Closure, Sensor-Guided Technologies and Esophageal Protection product lines, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. Financial information concerning these segments is provided in Note 18, Segment and Enterprise-Wide Information, within the consolidated financial statements in Item 8 of this Annual Report on Form 10-K. We believe that Plasma and Hospital have the greatest growth potential and are well positioned to drive long-term value. Blood Center operates in more challenging markets, and we have sharpened our focus accordingly on targeted opportunities – particularly in plasma and platelets – while ensuring continued alignment of this business with our broader strategic objectives. Recent Developments Acquisitions Vivasure Medical Limited On January 9, 2026, we acquired all of the outstanding equity interests of Vivasure for a net purchase price of $164.4 million. The net purchase price included $60.2 million paid in cash at closing, net of $0.4 million cash acquired and after giving effect to the value of certain prior investments and loans we made to Vivasure, as well as other customary closing adjustments, and the fair value of contingent consideration of $20.7 million. The contingent consideration is based on sales growth over the three years following the completion of the acquisition and the achievement of certain other milestones, and is also subject to adjustments based on the value of certain prior investments and loans. The Company financed this transaction through available cash on hand. Vivasure is a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure. Vivasure’s PerQseal Elite system uses a proprietary bioabsorbable patch to seal large-bore (up to 26 F) arteriotomies and venotomies from inside the vessel, offering a sutureless, fully absorbable solution for structural heart and endovascular procedures. In 2025, Vivasure submitted a premarket approval, or PMA, application to the FDA for the PerQseal Elite arterial closure system and received CE Mark in Europe for both arterial and venous indications. The addition of Vivasure expands our Hospital business unit portfolio in the interventional cardiology market and will be included in the Hospital reportable segment. Share Repurchase Programs In accordance with our previously announced three-year share repurchase program, During the fourth quarter of fiscal 2026, we repurchased $25.0 million of our common stock pursuant to a previously executed Rule 10b5-1 trading plan. The total number of shares repurchased pursuant to the Rule 10b5-1 trading plan was 360,457 at an average price per share upon final settlement of $69.36. Additionally, in March 2026, we completed a $75.0 million repurchase of our common stock pursuant to an ASR entered into with Goldman Sachs in February 2026. The total number of shares repurchased under the ASR was 1,218,798 at an average price per share upon final settlement of $61.54. As of March 28, 2026, the total remaining authorization for repurchases of our common stock under the share repurchase program was $325.0 million. 36 Table of Contents Convertible Debt Repayment and Revolving Credit Facility Drawdown On March 2, 2026, we repaid in full at maturity our outstanding 2026 Notes for an aggregate amount of $300.0 million in cash, representing the outstanding principal amount of the 2026 Notes. The repayment was funded with cash on hand and borrowings under the Company’s revolving credit facility. No holders exercised conversion rights with respect to the 2026 Notes prior to the close of business on the second scheduled trading day immediately preceding the maturity date. The capped call transactions entered into in connection with the issuance of the 2026 Notes expired in accordance with their terms upon the maturity of the 2026 Notes. Market Trends Plasma Market There are two key aspects to the market for our plasma products - the growth in demand for plasma-derived biopharmaceuticals and the limited number of significant biopharmaceutical companies in this market. Changes in demand for plasma-derived therapies, particularly immunoglobulin, are the key driver of plasma collection volumes in the plasma biopharmaceutical market. Various factors related to the supply of plasma and the production of plasma-derived therapies also affect collection volume, including the following: •Biopharmaceutical companies continue to increase yield from plasma collections in order to meet growing demand for plasma-derived therapies without requiring an equivalent increase in plasma donations; •Newly approved indications for diseases treated with plasma-derived therapies, the growing understanding and diagnosis of diseases treatable with plasma derived therapies, longer lifespans and a growing aging patient population increase the demand for plasma; and •Expansion in the availability of plasma-derived therapies across new geographic markets also increases demand for plasma. Despite the overall growth in the market, there are few biopharmaceutical companies that collect and fractionate source plasma. Significant barriers to entry exist for new entrants due to high capital outlay requirements for fractionation, long regulatory pathways to the licensing of collection centers and fractionation facilities and approval of plasma-derived biopharmaceuticals. As a result, there are relatively few customers for our Plasma products, especially in the U.S. where over two-thirds of the world’s source plasma is collected and only a few customers provide the majority of our Plasma revenue. However, certain jurisdictions, such as Egypt, Canada, Belgium and the United Kingdom have begun or expanded dedicated programs to collect plasma for fractionation for their local needs, which has expanded the Plasma market. Blood Center Market In the Blood Center market, we sell automated blood component collection systems. While we sell products around the world, a significant portion of our sales are to a limited number of customers due to the relatively limited number of blood collectors. Within the Blood Center market, we have seen two trends that have negatively impacted growth of the overall marketplace despite the overall increase in aging populations: •Declining transfusion rates in mature markets due to the development of more minimally invasive procedures with lower associated blood loss as well as better blood management; and •Competition in multi-unit collection technology for automated blood component collection systems has intensified and has negatively impacted our sales in markets where these collections are prevalent. As Blood Center operates in more challenging markets, we have sharpened our focus accordingly on targeted opportunities – particularly in plasma and platelets – while ensuring continued alignment of this business with the Company’s broader strategic objectives. 37 Table of Contents Hospital Markets Interventional Technologies: Vascular Closure Market - The target markets for our vascular closure products used in coronary, structural heart, peripheral and electrophysiology procedures, are highly concentrated in the U.S. The mature market of coronary and peripheral procedures consists of interventions to diagnose and treat vascular diseases. Our products also address many of the vascular closure needs for the structural heart (“contralateral access sites”) and electrophysiology procedures. In August 2024, we successfully launched the VASCADE MVP XL, which allowed us to capitalize more broadly in procedures as part of electrophysiology, coronary and peripheral markets. In January 2026, we successfully completed the acquisition of Vivasure, which included the PerQseal Elite large bore closure system, which is designed for percutaneous vessel closure following catheter-based procedures requiring large bore femoral access, including TAVR, EVAR and mechanical circulatory support procedures. PerQseal Elite has received CE Mark in Europe for arterial and venous indications, and we have submitted a PMA application to the FDA for an arterial indication in the United States. We believe PerQseal Elite complements and expands our Vascular Closure portfolio into the large bore market. Sensor-Guided Technologies Market - The market for sensor-guided technologies reflects varying dynamics across different interventional cardiology procedures. In the TAVR market, characterized by high growth, the demand for innovative solutions like SavvyWire is driven by an aging population and increasing prevalence of aortic valve diseases globally. Conversely, in the more mature percutaneous coronary intervention (“PCI”) market, the steady demand for sensor-guided technologies such as OptoWire remains driven by persistent prevalence of coronary artery disease, emphasizing the need for advanced diagnostic and therapeutic interventions. Our strategic investment in sensor-guided technologies positions us to capitalize on these trends, leveraging innovation to address evolving needs in both high-growth and mature markets while expanding our global market presence through initiatives such as receiving CE Mark for our Savvywire. Esophageal Protection Market - The market for esophageal protection devices, such as our ensoETM, is driven by radiofrequency, or RF, ablation for the treatment of atrial fibrillation, which has a risk of thermal injury to the esophagus. One of the perceived benefits of pulse field ablation, or PFA, is that its mechanism of action is tissue selective, which is believed to spare the esophagus from serious injury and may, therefore, obviate the need for esophageal cooling devices. While there are cardiac ablation procedures currently performed using RF ablation, the immediate opportunity for esophageal cooling during an atrial fibrillation ablation has substantially diminished over the last two years due to the launch of PFA in the US and Japan. PFA has been available in Europe for several years already. Blood Management Technologies: Hemostasis Management Market - The use of routine coagulation testing is well established throughout the world in various medical procedures, including cardiovascular surgery, organ transplantation, trauma, post-partum hemorrhage and percutaneous coronary intervention. While standard tests like prothrombin time, partial thromboplastin time and platelet count have limited ability to reveal a patient’s risk for bleeding, they do not provide information on the patient’s risk for thrombosis. In addition, these routine tests do not provide specific data about clot quality or stability. As a result of these limitations, clinicians are increasingly utilizing advanced hemostasis testing to provide more information about a patient’s hemostasis status, resulting in improved clini [Excerpt truncated for page length; the complete text is on the linked full-MD&A page.] Read the full FY 2026 MD&A: /company/HAE/mda/fy2026/ All MD&A years: /company/HAE/mda/ ## MD&A history Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page. - [FY 2025 MD&A](/company/HAE/mda/fy2025/): filed 2025-05-21; accession 0000313143-25-000025 (https://www.sec.gov/Archives/edgar/data/313143/000031314325000025/hae-20250329.htm) - [FY 2024 MD&A](/company/HAE/mda/fy2024/): filed 2024-05-20; accession 0000313143-24-000020 (https://www.sec.gov/Archives/edgar/data/313143/000031314324000020/hae-20240330.htm) - [FY 2023 MD&A](/company/HAE/mda/fy2023/): filed 2023-05-22; accession 0000313143-23-000014 (https://www.sec.gov/Archives/edgar/data/313143/000031314323000014/hae-20230401.htm) - [FY 2022 MD&A](/company/HAE/mda/fy2022/): filed 2022-05-25; accession 0000313143-22-000024 (https://www.sec.gov/Archives/edgar/data/313143/000031314322000024/hae-20220402.htm) ## Macro cross-references Indicators mapped to this company's SIC classification (industry 3841 Surgical & Medical Instruments & Apparatus) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim. - [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index - [TCU](/indicator/TCU/): Capacity Utilization: Total Index - [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities - [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product - [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity - [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate - [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private - [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/). All macro indicators: /indicators/ ## For LLMs & downloads Markdown twin: /company/HAE.md · JSON record: /company/HAE.json · verified financials: /company/HAE/financials.json / /company/HAE/financials.csv · machine TOC for the whole site: /llms.txt